LLY vs NKE: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and NIKE, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-17.
Eli Lilly and Company · Healthcare
$1,179.09
+31.7% upside to fair value
High Conviction
Grade A
High Quality
VS
NIKE, Inc. · Consumer Cyclical
$41.05
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
NKE has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
NKE |
| Current Price |
$1,179.09 |
$41.05 |
| Fair Value Estimate |
$1,552.32 |
$59.52 |
| Upside to Fair Value |
+31.7%
|
+45.0%
|
| Market Cap |
$1,110.4B |
$60.7B |
| Forward P/E |
—
|
19.6x
|
| EV / EBITDA |
34.3x
|
14.2x
|
| Price / Sales |
14.6x
|
1.3x
|
| Price / FCF |
77.7x
|
57.9x
|
| Revenue Growth YoY |
+55.5%
|
-1.1%
|
| Gross Margin |
83.5%
|
42.9%
|
| Operating Margin |
45.9%
|
8.2%
|
| Return on Equity |
101.3%
|
22.0%
|
| Dividend Yield |
0.55% |
0% |
| FCF Yield |
1.29%
|
1.73%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly is a global biopharma company whose exceptionally profitable cardiometabolic franchises, led by Mounjaro and Zepbound, are driving a high-quality growth phase: revenue rose 55.5% year over year and earnings rose 168.0% year over year in the most recent quarter, while gross, operating, and net margins were 83.5%, 45.9%, and 35.0%, respectively. Business quality is high because tirzepatid…
NIKE, Inc. is a leading global athletic footwear and apparel company with a durable competitive moat supported by its strong brand, scale, and global distribution infrastructure. The company is currently led by CEO Elliott Hill, a seasoned Nike veteran who returned in October 2024 to navigate intensifying competition and channel complexity. Despite its market leadership and solid profitability me…
Accumulation Zones
| Metric |
LLY |
NKE |
| Zone Low |
$1,164.24 |
$44.64 |
| Zone High |
$1,319.47 |
$50.59 |
| In Buy Zone? |
Yes
|
Yes
|